Work

U-BIOPRED: evaluation of the value of a public–private partnership to industry

Year: 2018

Type: review

Source: Drug Discovery Today

DOI: 10.1016/j.drudis.2018.06.015

Authors: John H. Riley, Veit J. Erpenbeck, John G. Matthews, Cecile T.J. Holweg, Christopher Compton, Wolfgang Seibold, Timothy Higenbottam, Scott Wagers, Anthony Rowe, David Myles

Institutions: GlaxoSmithKline (United Kingdom), Novartis (Switzerland), Genentech, Boehringer Ingelheim (Germany), Allergy Therapeutics (United Kingdom)

Language: English

Topic: University-Industry-Government Innovation Models

Subfield: Management of Technology and Innovation

Field: Business, Management and Accounting

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: European Federation of Pharmaceutical Industries and Associations, European Commission

OpenAlex ID: W2809425658

FWCI: 0.532

Cites: 38

Cited by: 18

Related to: 10